Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- recombinant proteins
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 183006
In December 2006, the Parties entered into a collaboration and option agreement to discover, develop and commercialize novel small molecule therapeutics, including omecamtiv mecarbil, The agreement granted an option to obtain an exclusive license worldwide, except Japan, to develop and commercialize omecamtiv mecarbil and other drug candidates arising from the collaboration.
In June 2013, the parties executed an amendment to include Japan, resulting in a worldwide collaboration. Under the Amendment, Parties conducted a Phase 1 pharmacokinetic study intended to support inclusion of Japan in a potential Phase 3 clinical development program and potential global registration dossier for omecamtiv mecarbil.
IPSCIO Record ID: 240469
The licensed property is Angiotensin-converting enzyme genetic variant screens; Transgenic model and treatment for heart disease; Transgenic Model for Heart Failure; Method for identifying adrenergic receptor antagonists having good tolerability; Diagnosis and treatment of myocardial failure; Method of treating heart failure; Inhibition of HDAC as a treatment for cardiac hypertrophy; and, Quantitative analysis of closely related protein isoforms using matrix-assisted laser desorption/ionization time of flight mass spectrometry.
IPSCIO Record ID: 28064
IPSCIO Record ID: 359108
Cannabidiol is a non-psychoactive molecule with broad therapeutic potential in the treatment of chronic inflammatory disease including heart failure.
Field of use to treat cardiovascular disease, cardiopulmonary disease, and cardiac arrhythmias.
IPSCIO Record ID: 28000
IPSCIO Record ID: 255044
Potential therapeutic mRNA medicines is directed at certain targets for the treatment of cardiovascular and cardiometabolic diseases and cancer, and agreed to provide related services.